Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Moderate to Severe Psoriasis
NCT01094093
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
73
Enrollment
INDUSTRY
Sponsor class
Conditions
Psoriasis
Interventions
DRUG:
AMG 139
Sponsor
AstraZeneca